inflammatory bowel disease

This Week in Science

In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.

Research suggests gut microbe representation, abundance, and function may provide clues for diagnosing Crohn's disease, ulcerative colitis, and irritable bowel syndrome.

The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.

Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.

The phenome-wide association study focused on SNPs near potential drug target sites with ties to one or more phenotypes that might impact target suitability.

In adults and children with Crohn's, miR-31 was found at higher levels in gut tissue, and the cases marked by lower expression tended to have poorer outcomes.

Researchers compared findings from genome-wide association studies for 62 traits or conditions with genes implicated in 20 Mendelian disorder types, uncovering new ties.

This Week in Nature

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.

Genome-wide polygenic risk scores highlight those at risk of coronary artery disease, atrial fibrillation, type 2 diabetes, IBD, and breast cancer.

Researchers integrated results from a pathogen-host association study with available clinical data to find variants influencing both infection responses and other disease risks.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.